Please login to the form below
Horizon appoints board chair
Dr Ian Gilham assumes position full-time
Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as its interim chairman.
The UK-based genetic research firm will look to benefit from Dr Gilham's thirty years of industry experience, which includes his role as CEO of in vitro diagnostics company Axis-Shield.
He held this role until from 2008 to 2011, when the company was acquired by Alere.
Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs.
Horizon's CEO Dr Darrin Disley said: “As interim chairman [Dr Gilham] has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organisation."
These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
